Omadacycline tosylate
Based on 33 publication(s) in Google Scholar
Omadacycline (PTK 0796) tosylate, a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline tosylate acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline tosylate possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline tosylate can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections.
For research use only. We do not sell to patients.
- Purity: 98.29%
- CAS No.: 1075240-43-5
- Formula: C36H48N4O10S
- Molecular Weight:728.85
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Covalent Screening Library
HY-L036
-
Antibacterial Compound Library
HY-L049
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Rare Diseases Drug Library
HY-L102
-
Off-patent Drug Library
HY-L141
-
Covalent Screening Library Plus
HY-L036P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Omadacycline tosylate
More- Nat Microbiol. 2026 Feb 6. [Abstract]
- Nat Microbiol. 2023 Mar;8(3):410-423. [Abstract]
- Nat Struct Mol Biol. 2023 Sep;30(9):1380-1392. [Abstract]
- PLoS Biol. 2022 Sep 28;20(9):e3001808. [Abstract]
- Virulence. 2022 Dec;13(1):77-88. [Abstract]
- J Clin Microbiol. 2020 Jan 28;58(2):e01603-19. [Abstract]
- Antibiotics (Basel). 2022 Sep 23;11(10):1298. [Abstract]
- Ann Lab Med. 2021 May 1;41(3):293-301. [Abstract]
- Antimicrob Agents Chemother. 2025 Jul 2;69(7):e0024925. [Abstract]
- Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0105124. [Abstract]
- Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0063824. [Abstract]
- Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0145922. [Abstract]
- Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02097-19. [Abstract]
- Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00470-19. [Abstract]
- Microbiol Spectr. 2023 Jun 15;11(3):e0071823. [Abstract]
- Microbiol Spectr. 2023 Feb 14;11(1):e0323822. [Abstract]
- J Antimicrob Chemother. 2021 Jul 15;76(8):2071-2078. [Abstract]
- J Antimicrob Chemother. 2021 Feb 11;76(3):653-658. [Abstract]
- Pathology. 2026 Feb 6:S0031-3025(26)00393-4. [Abstract]
- J Microbiol Immunol Infect. 2025 Apr;58(2):219-225. [Abstract]
- Open Forum Infect Dis. 2024 Oct 11;11(11):ofae611. [Abstract]
- J Glob Antimicrob Resist. 2025 Aug 8:44:435-441. [Abstract]
- Malar J. 2025 Jun 19;24(1):194. [Abstract]
- Infect Drug Resist. 2025 Oct 4:18:5239-5247. [Abstract]
- Animal Feed Science and Technology. 2014 Dec;198:323-332.
- J Antibiot (Tokyo). 2026 May 27. [Abstract]
- J Antibiot (Tokyo). 2022 Aug;75(8):463-471. [Abstract]
- Clin Exp Pharmacol Physiol. 2023 Jul;50(7):604-609. [Abstract]
- Diagn Microbiol Infect Dis. 2020 Nov;98(3):115129. [Abstract]
- bioRxiv. 2026 Jan 14.
- Cureus. 2024 Dec 1;16(12):e74917. [Abstract]
- Comput Intell Neurosci. 2022 Apr 25;2022:7636983. [Abstract]
- Research Square Preprint. 2020 Jun.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
All Antibiotic Isoforms
More
Biological Activity
|
Tetracycline |
Omadacycline displays activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), beta-hemolytic streptococci, penicillin-resistant Streptococcus pneumonia (PRSP) and Haemophilus influenzae (H. influenzae), with MIC90s of 1.0, 0.25, 0.5, 0.25 and 2.0 μg/mL respectively[2].
Omadacycline is active against strains expressing tetracycline and other antibiotics resistance by ribosomal protection and active tetracycline efflux[2].
Omadacycline (10 μM) inhibits the ligand binding activity of muscarinic acetylcholine receptor (M2) by 82%[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1075240-43-5
-
Appearance Solid
-
Molecular Weight 728.85
-
Formula C36H48N4O10S
-
Color White to yellow
-
SMILES
O=C(C1=C(O)[C@@H](N(C)C)[C@@](C[C@@]2([H])C(C(C3=C(O)C(CNCC(C)(C)C)=CC(N(C)C)=C3C2)=O)=C4O)([H])[C@@]4(O)C1=O)N.OS(=O)(C5=CC=C(C)C=C5)=O
-
Synonyms
PTK 0796 tosylate; Amadacycline tosylate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (33)
-
Journal Impact Factor
-
Most Recent
-
Nat Microbiol
Addendum: ESKAPE pathogens rapidly develop resistance against antibiotics in development in vitro. [Abstract]2026 Feb 6. PMID: 41652022 -
Nat Microbiol
Characterization of antibiotic resistomes by reprogrammed bacteriophage-enabled functional metagenomics in clinical strains. [Abstract]2023 Mar;8(3):410-423. PMID: 36759752 -
Nat Struct Mol Biol
2023 Sep;30(9):1380-1392. PMID: 37550453 -
PLoS Biol
Low levels of tetracyclines select for a mutation that prevents the evolution of high-level resistance to tigecycline. [Abstract]2022 Sep 28;20(9):e3001808. PMID: 36170241 -
Virulence
MALDI-TOF MS for rapid detection and differentiation between Tet(X)-producers and non-Tet(X)-producing tetracycline-resistant Gram-negative bacteria. [Abstract]2022 Dec;13(1):77-88. PMID: 34951562 -
J Clin Microbiol
Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole. [Abstract]2020 Jan 28;58(2):e01603-19. PMID: 31748318 -
Antibiotics (Basel)
Evaluating the Efficacy of Eravacycline and Omadacycline against Extensively Drug-Resistant Acinetobacter baumannii Patient Isolates. [Abstract]2022 Sep 23;11(10):1298. PMID: 36289956 -
Ann Lab Med
In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis. [Abstract]2021 May 1;41(3):293-301. PMID: 33303714 -
Antimicrob Agents Chemother
An enoyl-ACP reductase inhibitor, NITD-916, expresses anti- Mycobacterium abscessus activity. [Abstract]2025 Jul 2;69(7):e0024925. PMID: 40407337 -
Antimicrob Agents Chemother
Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA of Mycobacterium abscessus. [Abstract]2024 Dec 5;68(12):e0105124. PMID: 39470195 -
Antimicrob Agents Chemother
Omadacycline powder for research procured from unauthorized commercial vendors may be impure and/or unstable. [Abstract]2024 Jul 9;68(7):e0063824. PMID: 38888320 -
Antimicrob Agents Chemother
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection. [Abstract]2023 Feb 16;67(2):e0145922. PMID: 36688684 -
Antimicrob Agents Chemother
Omadacycline Efficacy against Enterococcus faecalis Isolated in China: In Vitro Activity, Heteroresistance, and Resistance Mechanisms. [Abstract]2020 Feb 21;64(3):e02097-19. PMID: 31871086 -
Antimicrob Agents Chemother
In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus. [Abstract]2019 May 24;63(6). pii: e00470-19. PMID: 30962331 -
Microbiol Spectr
Omadacycline, Eravacycline, and Tigecycline Express Anti-Mycobacterium abscessus Activity In Vitro. [Abstract]2023 Jun 15;11(3):e0071823. PMID: 37140428 -
Microbiol Spectr
In Vitro Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria. [Abstract]2023 Feb 14;11(1):e0323822. PMID: 36475850
Omadacycline tosylate purchased from MedChemExpress. Usage Cited in: Microbiol Spectr. 2023 Feb 14;11(1):e0323822. [Abstract]
The MIC distributions of Omadacycline against 43 M. fortuitum isolates. The y axis shows the number of strains with each MIC value, with the specific numbers shown above the bars.
-
J Antimicrob Chemother
In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. [Abstract]2021 Jul 15;76(8):2071-2078. PMID: 33956969 -
J Antimicrob Chemother
Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods. [Abstract]2021 Feb 11;76(3):653-658. PMID: 33258923 -
Pathology
In vitro activity of recently introduced Gram-positive-specific antimicrobial agents against Australian methicillin-resistant Staphylococcus aureus isolates. [Abstract]2026 Feb 6:S0031-3025(26)00393-4. PMID: 41760492 -
J Microbiol Immunol Infect
Antimicrobial resistance among imipenem-non-susceptible Escherichia coli and Klebsiella pneumoniae isolates, with an emphasis on novel β-lactam/β-lactamase inhibitor combinations and tetracycline derivatives: The Taiwan surveillance of antimicrobial resistance program, 2020-2022. [Abstract]2025 Apr;58(2):219-225. PMID: 39934015 -
Open Forum Infect Dis
Successful Treatment of Recurrent Extensively Drug-Resistant Elizabethkingia anophelis Bacteremia Secondary to Ventricular Assist Device-Associated Infection. [Abstract]2024 Oct 11;11(11):ofae611. PMID: 39494452 -
J Glob Antimicrob Resist
Susceptibility of multidrug-resistant Escherichia coli and Klebsiella pneumoniae to oral antibiotics in Australia. [Abstract]2025 Aug 8:44:435-441. PMID: 40784378 -
Malar J
2025 Jun 19;24(1):194. PMID: 40537756 -
Infect Drug Resist
In vitro Activity of the Novel Tetracyclines Derivative, Zifanocycline Against Mycobacterium abscessus. [Abstract]2025 Oct 4:18:5239-5247. PMID: 41069760 -
-
J Antibiot (Tokyo)
Combined effect of eravacycline and omadacycline with other antimicrobial agents against Acinetobacter Baumannii. [Abstract]2026 May 27. PMID: 42204275 -
J Antibiot (Tokyo)
Comparison of antibacterial activities and resistance mechanisms of omadacycline and tigecycline against Enterococcus faecium. [Abstract]2022 Aug;75(8):463-471. PMID: 35760902 -
Clin Exp Pharmacol Physiol
In vitro susceptibility testing of tetracycline-class antibiotics against slowly growing non-tuberculous mycobacteria. [Abstract]2023 Jul;50(7):604-609. PMID: 37086075 -
Diagn Microbiol Infect Dis
In vitro activity of new tetracycline analogues omadacycline and eravacycline against clinical isolates of Helicobacter pylori collected in China. [Abstract]2020 Nov;98(3):115129. PMID: 32739761 -
-
Cureus
2024 Dec 1;16(12):e74917. PMID: 39742159 -
Comput Intell Neurosci
Omadacycline Efficacy against Streptococcus Agalactiae Isolated in China: Correlation between Resistance and Virulence Gene and Biofilm Formation. [Abstract]2022 Apr 25;2022:7636983. PMID: 35510054 -
Solvent & Solubility
H2O : 10 mg/mL (13.72 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (68.60 mM); Clear solution; Need ultrasonic
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Handling Instructions (2659 KB)
References
[1]. Durães F, et, al. Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines. Pharmaceuticals (Basel). 2019 Apr 21;12(2):63. [Content Brief]
[2]. Macone AB, et, al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58(2):1127-35. [Content Brief]
[3]. Zhanel GG, et, al. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. Drugs. 2020 Feb;80(3):285-313. [Content Brief]
[4]. Markham A, et, al. Omadacycline: First Global Approval. Drugs. 2018 Dec;78(18):1931-1937. [Content Brief]
[5]. Tanaka SK, et al. In Vitro and In Vivo Assessments of Cardiovascular Effects with Omadacycline. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5247-53. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 1.3720 mL | 6.8601 mL | 13.7202 mL | 34.3006 mL |
| 5 mM | 0.2744 mL | 1.3720 mL | 2.7440 mL | 6.8601 mL | |
| 10 mM | 0.1372 mL | 0.6860 mL | 1.3720 mL | 3.4301 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Omadacycline tosylate Related Classifications
HY-14865B Related Classifications
Powered by Bioz